Myomo logo

Myomo

Myomo is a maker of the MyoPro powered arm brace for people with arm and hand paralysis, founded in 2004 and based in Burlington, Massachusetts. Medicare pays $33,481 or $65,872 depending on the model.8,2,5

Robotics Reviewed Editorial TeamUpdated November 10, 2026myomo.com

Our take

Myomo is the clearest medical robotics business in this group to understand from the outside. Its MyoPro brace reads weak muscle signals in a paralyzed arm and powers the elbow and hand, Medicare publishes what it pays for the device, and the company reports orders, average selling price, and patient pipeline every quarter.6,5,3

It is still small and unprofitable. Revenue was $40.9 million in 2025, and Myomo expects $45 million to $47 million in 2026. It had $13.5 million in cash and short-term investments at June 30, 2026.4,3

Scores by criterion

Myomo scores out of 10
Pricing transparency6.8
Product maturity8.0
Deployment evidence7.8
Company durability6.4
Ease of integration6.0
Overall score (average of the five)7.0

Each criterion is defined on our methodology page.

Who uses Myomo and what it's for

MyoPro is prescribed for people with weakness or partial paralysis in the arm and hand after a stroke, brachial plexus injury, or other neuromuscular condition.1,6 It is referred at rehabilitation centers including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, and twenty Veterans Affairs hospitals.2

The buyer is usually an insurer. Myomo says it has in-network access to more than 100 million covered lives, including Medicare and VA patients, and in 2026 added state contracts with Anthem Blue Cross Blue Shield plans.3

A brace driven by the wearer’s own muscle signals

When the wearer tries to move, sensors in the brace detect the weak muscle signal and a motor moves the arm in that direction, so the person controls the motion. Myomo says this lets users feed themselves, carry objects, and do household tasks.6

The technology came from MIT and Harvard Medical School research. Myomo licensed MIT's patents in 2006, and its first robotic elbow brace received FDA approval in 2007.6,7

Orders and referrals reported each quarter

In the second quarter of 2026 Myomo booked a record 255 orders, added 739 patients to its pipeline, and reported an average selling price of about $55,500. Revenue rose 21% to $11.7 million while operating expenses grew less than 1%.3

More than half of that quarter's revenue came from recurring sources such as clinician referrals, orthotic and prosthetic partners, and the VA. A randomized controlled trial at the University of Utah had enrolled 25 of a planned 50 subjects.3

Second quarter 2026 revenue was $11.7 million, up 21% from a year earlier, with a gross margin of 72.1%. Myomo guided third quarter revenue to $11.5 million to $12.0 million, up 14% to 19%, and expects cash burn below $2 million in the second half of 2026.11,12

On November 9, 2026 Myomo reported record third quarter revenue of $12.3 million, up 22% from a year earlier, on 222 MyoPro units at an average selling price of about $55,500. Gross margin rose to 71.3%, orders reached a record 258, recurring patient sources made up 54% of revenue, and Adjusted EBITDA was about breakeven (a loss of $1,513). The net loss was $4.2 million, including a $1.8 million non-cash charge, cash and short-term investments were $11.9 million, and the University of Utah trial had enrolled 35 of a planned 50 subjects. Myomo narrowed full-year 2026 revenue guidance to $46 million to $47 million.30

Prices set by Medicare

The Centers for Medicare and Medicaid Services set fee schedule rates of $33,480.90 for the MyoPro Motion W and $65,871.74 for the Motion G, effective April 1, 2024.5 Because private insurers and the VA negotiate their own rates, the average selling price Myomo reports is the best guide to what the device brings in.3

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for patients and clinicsTop rated, for large hospitalsLower score, for patients and clinicsLower score, for large hospitalsNot yet reviewed45678910Review Score← Patients and clinicsLarge hospital systems →Who it's built for7.06.16.66.35.9
Myomo and its competitors
CompanyProductPricing modelDeployment footprintWhere Myomo wins or loses
MyomoMyoPro powered arm and hand brace1Medicare fee schedule rates of $33,481 and $65,8725Patients reached through clinician referrals and orthotics and prosthetics channels3,4Published Medicare rate and quarterly reporting; small, unprofitable company
KanduFDA-cleared brain-computer interface for at-home stroke therapy13Prescription device billed under HCPCS E0738 as a Medicare capped rental13Chronic stroke survivors at least six months post-stroke13IpsiHand wins as a therapy device for stroke recovery at home. MyoPro wins for patients who need powered help with daily arm use and for conditions beyond stroke.
VivistimImplanted vagus nerve stimulator paired with rehabilitation14Not published14FDA approved for upper limb recovery after ischemic stroke14Vivistim wins for patients who want therapy gains without wearing a device. MyoPro wins by avoiding surgery.
CyberdyneMedical HAL wearable robot driven by the wearer's bioelectric signals18Not published; mainly rentals and treatment services19Approvals or certifications in more than 20 countries27Myomo wins for arm and hand weakness. Cyberdyne wins for patients relearning to walk.
Ekso BionicsEksoNR exoskeleton for gait training after stroke and brain injury21Not published21Inpatient rehabilitation facilities; first exoskeleton FDA-cleared for stroke21Ekso wins for walking practice in the clinic. MyoPro wins for daily arm and hand use at home.
LifewardReWalk personal exoskeleton and AlterG anti-gravity systems23Medicare fee of $91,032 for a personal exoskeleton22Individual users through Medicare and insurers; AlterG in more than 4,000 facilities22Lifeward wins on walking for people with spinal cord injury. Myomo wins on arm and hand function.
WandercraftAtalante X and Eve self-balancing exoskeletons28Not published28Devices in more than 700 rehabilitation centers after buying Ekso29Myomo wins for arm and hand weakness. Wandercraft wins for people who need help to stand and walk.

Limits

Every unit has to be prescribed, custom fitted by a trained clinician, and approved by an insurer, which slows adoption and makes the path to a device longer than a typical purchase.2,3

Losses continue. Myomo reported a net loss of $4.0 million in the second quarter of 2026, including a $1.2 million non-cash charge.3

Guidance has moved around. In 2025 Myomo lowered its full-year revenue guidance to $40 million to $42 million and reported a wider second-quarter loss, and AInvest reported that its shares fell about 9% in a September 17, 2025, session after those results. In 2026 it raised guidance.10,3

What customers say

Where it helps

It’s giving me a sense of self-sufficiency, and to me, that’s pride.

Myomo also points to published clinical research showing an immediate, clinically significant reduction in upper extremity impairment with MyoPro.2

Where it falls short

We found no independent patient reviews to quote. The drawbacks in public material are insurance approval, the fitting process, and the company's continued losses.3

Where customer reviews couldn't be found, our analysts attempted to give a voice to buyer sentiment, drawing on real information from review sites, forums and product documentation. Based on: Myomo financial results, Medicare fee schedule announcement, and patient stories.

Leadership

  • Paul R. Gudonis

    Paul R. Gudonis

    Chairman and chief executive officer

    Gudonis has led Myomo since 2011. He previously ran Genuity and Centra Software and helped introduce AT&T's first cellular service.15

    Read full profile

  • Katie McClure

    Katie McClure

    Chief commercial officer

    McClure leads Myomo's commercial organization.9

  • David Henry

    David Henry

    Chief financial officer

    Henry is Myomo's chief financial officer.9

  • Dr. Harry Kovelman

    Dr. Harry Kovelman

    Chief medical officer

    Dr. Kovelman is Myomo's chief medical officer.9

Sources

  1. Myomo, Homepage, accessed November 3, 2026
  2. Myomo, About us, accessed November 3, 2026
  3. Myomo, Second quarter 2026 results, SEC exhibit 99.1, August 5, 2026, accessed November 3, 2026
  4. Myomo, Fourth quarter and full year 2025 results, accessed November 3, 2026
  5. Myomo, CMS posts final Medicare DMEPOS fee schedule rate for the MyoPro, March 1, 2024, accessed November 3, 2026
  6. Myomo, Myomo launches initial public offering via JOBS Act Regulation A+, March 15, 2017, accessed November 3, 2026
  7. AUTM Better World Project, Myomo e100 NeuroRobotic System, accessed November 3, 2026
  8. Myomo, Prospectus filed with the SEC, 2020, accessed November 3, 2026
  9. Myomo, Management, accessed November 3, 2026
  10. AInvest, Myomo (MYO) shares plunge 9.09% as revised 2025 forecast and wider Q2 losses spur investor fears, September 17, 2025, accessed November 3, 2026
  11. Business Wire via Yahoo Finance, Myomo reports second quarter 2026 financial and operating results, August 5, 2026, accessed November 3, 2026
  12. Myomo, Myomo to report third quarter 2026 financial results on November 9, November 2, 2026, accessed November 10, 2026
  13. Neurolutions, For clinicians, accessed November 3, 2026
  14. Vivistim, Homepage, accessed November 3, 2026
  15. Myomo, Paul Gudonis leadership profile, accessed November 3, 2026
  16. Neurolutions, Homepage, accessed November 6, 2026
  17. Neurolutions, Merger announcement, accessed November 6, 2026
  18. Cyberdyne, Medical HAL lower limb type, accessed November 2, 2026
  19. Cyberdyne, Financial results briefing for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
  20. Cyberdyne, Consolidated financial results for the fiscal year ended March 31, 2026, May 14, 2026, accessed November 3, 2026
  21. Ekso Bionics, EksoNR, accessed November 1, 2026
  22. Lifeward, Form 10-Q for the quarter ended September 30, 2024, accessed November 1, 2026
  23. Lifeward, Fourth quarter and full year 2025 financial results, accessed November 1, 2026
  24. Wandercraft, Atalante X, accessed November 1, 2026
  25. Wandercraft, Eve personal exoskeleton, accessed November 1, 2026
  26. Wandercraft, Wandercraft acquires Ekso Bionics, accessed November 1, 2026
  27. Cyberdyne, About Cyberdyne, accessed November 3, 2026
  28. Wandercraft, Homepage, accessed November 2, 2026
  29. IZON, Wandercraft acquires Ekso Bionics to form major exoskeleton player, accessed November 2, 2026
  30. Myomo, Third quarter 2026 results, SEC exhibit 99.1, November 9, 2026, accessed November 10, 2026